These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 34390565)

  • 1. [Pathophysiological mechanisms of major mental disorders related to cardiovascular disease].
    Theodosis-Nobelos P; Asimakopoulou E; Madianos M
    Psychiatriki; 2022 Jun; 33(2):113-123. PubMed ID: 34390565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.
    Moteshafi H; Zhornitsky S; Brunelle S; Stip E
    Drug Saf; 2012 Oct; 35(10):819-36. PubMed ID: 22967188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing the safety and efficacy of atypical antipsychotics in psychiatric patients with comorbid medical illnesses.
    Newcomer JW
    J Clin Psychiatry; 2009; 70 Suppl 3():30-6. PubMed ID: 19570499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC).
    De Hert M; Dekker JM; Wood D; Kahl KG; Holt RI; Möller HJ
    Eur Psychiatry; 2009 Sep; 24(6):412-24. PubMed ID: 19682863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
    Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
    Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Schizophrenia, diabetes mellitus and antipsychotics].
    Gury C
    Encephale; 2004; 30(4):382-91. PubMed ID: 15538314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical risk in patients with bipolar disorder and schizophrenia.
    Newcomer JW
    J Clin Psychiatry; 2006 Nov; 67(11):e16. PubMed ID: 17201046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased Cardiovascular Disease Risk in Veterans With Mental Illness.
    Vance MC; Wiitala WL; Sussman JB; Pfeiffer P; Hayward RA
    Circ Cardiovasc Qual Outcomes; 2019 Oct; 12(10):e005563. PubMed ID: 31547692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Right care, first time: a highly personalised and measurement-based care model to manage youth mental health.
    Hickie IB; Scott EM; Cross SP; Iorfino F; Davenport TA; Guastella AJ; Naismith SL; Carpenter JS; Rohleder C; Crouse JJ; Hermens DF; Koethe D; Markus Leweke F; Tickell AM; Sawrikar V; Scott J
    Med J Aust; 2019 Nov; 211 Suppl 9():S3-S46. PubMed ID: 31679171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The comorbidity of bipolar disorder and cardiovascular diseases from pharmacotherapy perspective.
    Vuksan-Cusa B; Marcinko D; Sagud M; Jakovljević M
    Psychiatr Danub; 2009 Sep; 21(3):382-5. PubMed ID: 19794361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular risk factors during second generation antipsychotic treatment are associated with increased C-reactive protein.
    Dieset I; Hope S; Ueland T; Bjella T; Agartz I; Melle I; Aukrust P; Røssberg JI; Andreassen OA
    Schizophr Res; 2012 Sep; 140(1-3):169-74. PubMed ID: 22817875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical risk in patients with bipolar disorder and schizophrenia.
    Newcomer JW
    J Clin Psychiatry; 2006; 67 Suppl 9():25-30; discussion 36-42. PubMed ID: 16965186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular risk factors among patients with schizophrenia, bipolar, depressive, anxiety, and personality disorders.
    Pérez-Piñar M; Mathur R; Foguet Q; Ayis S; Robson J; Ayerbe L
    Eur Psychiatry; 2016 May; 35():8-15. PubMed ID: 27061372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mental disorders and metabolic syndrome: a fatamorgana or warning reality?
    Jakovljević M; Crncević Z; Ljubicić D; Babić D; Topić R; Sarić M
    Psychiatr Danub; 2007 Jun; 19(1-2):76-86. PubMed ID: 17603420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mental illness and cardiovascular health: observational and polygenic score analyses in a population-based cohort study.
    Veeneman RR; Vermeulen JM; Bialas M; Bhamidipati AK; Abdellaoui A; Munafò MR; Denys D; Bezzina CR; Verweij KJH; Tadros R; Treur JL
    Psychol Med; 2024 Apr; 54(5):931-939. PubMed ID: 37706306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypertension and psychosis.
    Sudarshan Y; Cheung BMY
    Postgrad Med J; 2023 Jun; 99(1171):411-415. PubMed ID: 37294717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a health screening clinic.
    Millar HL
    Eur Psychiatry; 2010 Jun; 25 Suppl 2():S29-33. PubMed ID: 20620883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications.
    Penninx BWJH; Lange SMM
    Dialogues Clin Neurosci; 2018 Mar; 20(1):63-73. PubMed ID: 29946213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors in antipsychotic drug selection: tolerability considerations.
    Nasrallah HA
    CNS Spectr; 2003 Nov; 8(11 Suppl 2):23-5. PubMed ID: 14978455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.